. . . . . . "DN-101 is produced by Novacea Inc. OHSU and Beer have significant financial interest in Novacea Inc., a company that has a commercial interest in the results of this research and technology. It is a newly formulated pill that contains high amounts of calcitriol, a naturally occurring hormone and the biologically active form of vitamin D."@en . . . . . "DN-101 delivers activated vitamin D in amounts that are far higher than the natural levels of this hormone. DN-101 provides Myelodysplastic Syndrome (MDS)MDS patients with high doses of calcitriol in a pill form. DN-101 in combination with docetaxel seems to improve overall survival and, interestingly, has a favorable safety profile compared with docetaxel alone. "@en . . . "investigational"@en . . . "# Brawer MK: Recent Progress in the Treatment of Advanced Prostate Cancer With Intermittent Dose-Intense Calcitriol (DN-101). Rev Urol. 2007 Winter;9(1):1-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17396166 # Beer TM, Javle M, Lam GN, Henner WD, Wong A, Trump DL: Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer. Clin Cancer Res. 2005 Nov 1;11(21):7794-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16278401"@en . . . . "DN-101"@en . . . . "Investigated for use/treatment in cancer/tumors (unspecified), lung cancer, myelodysplastic syndrome, and prostate cancer."@en . . . . . . . . . . . .